ProQR Announces Proposed Underwritten Public Offering of Ordinary Shares Press release LEIDEN, Netherlands & CAMBRIDGE, Mass., Oct. October 22, 2024
ProQR Therapeutics Announces Transaction Completed for Théa to Acquire Sepofarsen and Ultevursen Ophthalmic Assets Press release Divestment of sepofarsen and ultevursen completed – Théa to continue development of sepofarsen and ultevursen for patients with LCA10 and Usher syndrome December 08, 2023
ProQR Prices $75 Million Underwritten Public Offering and Concurrent Private Placement Press release LEIDEN, Netherlands and CAMBRIDGE, Mass., Oct. 22, 2024 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. October 23, 2024
ProQR to Participate in the LifeSci 2nd Annual Genetic Medicines Symposium Press release LEIDEN, Netherlands & CAMBRIDGE, Mass., June 28, 2022 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. June 28, 2022
ProQR to Participate in the Kempen Life Sciences Conference Press release LEIDEN, Netherlands & CAMBRIDGE, Mass., April 19, 2022 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. April 19, 2022
ProQR to Present at Upcoming Scientific Meeting and Investor Conference Press release LEIDEN, the Netherlands, Feb. 06, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. February 06, 2018
ProQR to Webcast Virtual Analyst Event on November 18 Press release LEIDEN, Netherlands & CAMBRIDGE, Mass., Nov. 11, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. November 11, 2021
ProQR Announces Expert Perspectives Conference Call Series Press release Initial call in the series will feature Usher syndrome and retinitis pigmentosa on June 22 June 12, 2020
ProQR to Present at the Retinal Cell and Gene Therapy Innovation Summit and the Association for Research in Vision and Ophthalmology (ARVO) 2022 Press release LEIDEN, Netherlands & CAMBRIDGE, Mass., April 26, 2022 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. April 26, 2022